-
Mashup Score: 3Giving More Options to Patients With DCIS - 2 hour(s) ago
Data from clinical trials presented at SABCS may help patients with DCIS better understand their management options to make informed choices.
Source: www.aacr.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 4Program - 4 hour(s) ago
Program for AACR Special Conference in Cancer Research: DNA Methylation, Clonal Hematopoiesis, and Cancer
Source: www.aacr.orgCategories: General Medicine News, Onc News and JournalsTweet-
Dirk Schuebeler, Victor Corces, and @ManelEsteller will discuss "Interpreting Methylation Signals" in a plenary at the AACR Special Conference on DNA Methylation, Clonal Hematopoiesis, and Cancer (Feb 1-4, San Diego). https://t.co/E5ThaKy2H3 #AACRmethylation25 @CorcesVictor https://t.co/ndp6iPvlL2
-
-
Mashup Score: 7
The ZEST clinical trial, designed to evaluate niraparib (Zejula) for the prevention of breast cancer recurrence in patients with circulating tumor DNA (ctDNA), failed to accrue enough patients positive for ctDNA.
Source: www.aacr.orgCategories: General Medicine News, Oncologists1Tweet-
The ZEST trial may offer insights for ctDNA-based predictions of breast cancer recurrence, including the appropriate timing of ctDNA testing, according to a presentation by Dr. Nicholas Turner at #SABCS24. https://t.co/fCPvIIUqoh @royalmarsdenNHS https://t.co/6m8Ov7IV9F
-
-
Mashup Score: 16Multimodal Machine Learning Model Effective at Predicting Response to CDK4/6 Inhibitors in HR-positive, HER2-negative Breast Cancer Patients - 7 hour(s) ago
Combining real-world clinical and genomic data resulted in a more accurate prediction of outcomes compared to examining clinical and genomic data separately.
Source: www.aacr.orgCategories: General Medicine News, Oncologists1Tweet-
A multimodal machine learning model was effective at predicting response to CDK4/6 inhibitors in patients with HR-positive, HER2-negative breast cancer, according to results presented by Dr. Pedram Razavi at #SABCS24. https://t.co/Ea6it0D7Ml @MSKCancerCenter https://t.co/C93eKD7r5y
-
-
Mashup Score: 7
Genomic testing helped identify which patients with node-negative, HR-positive, HER2- negative breast cancer could benefit from the addition of anthracyclines to chemotherapy regimen.
Source: www.aacr.orgCategories: General Medicine News, Oncologists1Tweet-
Patients with high-risk, HR-positive, HER2-negative breast cancer had better outcomes when treated with the addition of anthracyclines to adjuvant taxane-based chemotherapy, according to results presented by Dr. Nan Chen at #SABCS24. https://t.co/DmgqU8cSC2 @UChicagoMed https://t.co/pk20rkfdJM
-
-
Mashup Score: 32025 FDA-AACR Workshop: DPD Deficiency and Weighing Potential Harms - 10 hour(s) ago
AACR is hosting a workshop with the FDA on January 16, 2025, to discuss the considerations for routine testing of DPD deficiency before treatment with fluoropyrimidines.
Source: www.aacr.orgCategories: General Medicine News, Oncologists1Tweet-
FDA Oncology and @AACR are jointly holding a workshop to discuss DPD deficiency testing, the current landscape and future directions. Hope to see many of you there on January 16, 2025 – register for in-person or virtual attendance. https://t.co/sR2xT0QGI0
-
-
Mashup Score: 2
AACR Special Conference in Cancer Research: Acute Lymphoblastic Leukemia
Source: www.aacr.orgCategories: General Medicine News, Oncologists1Tweet-
Submit an abstract by December 30 for the AACR Special Conference on Acute Lymphoblastic Leukemia (March 7-9, San Diego), organized in association with the AACR Hematologic Malignancies Working Group. Learn more: https://t.co/ggQLqXRI8v #aacrALL25 https://t.co/3N6mvuh8S2
-
-
Mashup Score: 4Program - 1 day(s) ago
Explore the program for the AACR Special Conference in Cancer Research: Translating Targeted Therapies in Combination with Radiotherapy.
Source: www.aacr.orgCategories: General Medicine News, Onc News and JournalsTweet-
Michael Baumann will deliver a keynote address at the AACR Conference on Translating Targeted Therapies in Combination with Radiotherapy (January 26-29, San Diego). Learn more: https://t.co/4RjYE1djQN #AACRradiation25 @_MichaelBaumann https://t.co/SrR2FxH2Dn
-
-
Mashup Score: 9
The one-year grant of $50,000 supports a postdoctoral or clinical research fellow conducting translational or clinical sarcoma research.
Source: www.aacr.orgCategories: General Medicine News, Oncologists1Tweet-
The AACR-QuadW Foundation Sarcoma Research Fellowship in Memory of Willie Tichenor is a one-year, $60,000 grant that supports postdoctoral or clinical research fellows conducting translational or clinical sarcoma research. Apply by January 9. Learn more: https://t.co/HlXwAknTFk https://t.co/Kxyvs2kC1p
-
-
Mashup Score: 7Most Patients With Intermediate-risk Breast Cancer May Safely Avoid Chest Wall Irradiation After Mastectomy - 1 day(s) ago
Patients with intermediate-risk breast cancer had similar rates of 10-year overall survival whether or not they underwent chest wall irradiation (CWI) after mastectomy.
Source: www.aacr.orgCategories: General Medicine News, Oncologists1Tweet-
Some patients with intermediate-risk breast cancer may safely avoid chest wall irradiation after mastectomy, according to results presented by Dr. Ian Kunkler at #SABCS24. https://t.co/hKtktOheH2 @EdinburghUni https://t.co/pY3BfRbb5P
-
Data from clinical trials presented at #SABCS24 may help patients with low-risk #DCIS, a noninvasive type of #breastcancer, choose between different management strategies. Learn more on the #AACRBlog: https://t.co/U0EXtvLoVa @SABCSSanAntonio @DrShelleyHwang @AnnPartridgeMD https://t.co/GgPeQlz7So